Program
AZD7798
A development code.
Its studies are mostly in Crohn Disease, led by AstraZeneca.
Furthest: phase 2, since May 8, 20245 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 52 open or running | phase 2since May 8, 2024 | Jul 6, 2022 | none ahead |
- Named in AstraZeneca’s own pipeline as
AZD7798
, phase 2, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 6, 2022First study: phase 1 study in Crohn DiseaseFirst studyNCT05452304 · 112 enrolled · United Kingdom
- Aug 30, 2023Phase 1 study in Crohn DiseaseNCT06053424 · 13 enrolled · Sweden
- May 8, 2024Phase 2 study in Crohn DiseaseNCT06450197 · 120 enrolled · United States, Argentina, Australia and more
- May 22, 2024Phase 1 study in Crohn DiseaseNCT06432764 · 9 enrolled · Sweden
- Sep 25, 2024Phase 2 study in Crohn DiseaseNCT06681324 · 24 enrolled · Belgium, Italy, Netherlands and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06681324Crohn Disease · Belgium, Italy, Netherlands and more | 2 | Active, not recruiting | Aug 10, 2026 | 24 |
| NCT06432764Crohn Disease · Sweden | 1 | Completed | Mar 27, 2026 | 9 |
| NCT06450197Crohn Disease · United States, Argentina, Australia and more | 2 | Active, not recruiting | Apr 30, 2026 | 120 |
| NCT06053424Crohn Disease · Sweden | 1 | Completed | Oct 8, 2024 | 13 |
| NCT05452304Crohn Disease · United Kingdom | 1 | Completed | Nov 14, 2024 | 112 |
How it is read
Names in the registry
- “AZD7798”, 5 entries
Codes read as this program: AZD7798.
Conditions, from the studies’ own filings
- Crohn Disease, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.